ArticleClinical and translational science2022

Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.

Yan Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.